The reason why refills are low is due to the fact that the vast number of endos aren't prescribing the drug mostly because they don't know about it or are ill informed.
Tudiabetes is a pathetically small number of diabetics and the fact you are using them as a barometer is laughable.
Afrezza will mostly be a niche drug in the United States but niche drugs can do well.
Time will tell if the new studies will help push endos to prescribe the drug.
After 3 years, the safety data shows it is a relatively safe drug compared to the other diabetes drugs out there.
News 
Market Data 
Discover 
